A sticker reminder intervention to promote intravenous-to-oral fluoroquinolone conversion: a cluster-randomized controlled trial
Abstract
Objective: To evaluate the effectiveness of a simple sticker reminder in increasing intravenous-to-oral (IV-to-PO) fluoroquinolone (FQ) conversion rates.
Design: Single-center, cluster-randomized controlled trial.
Setting: Forty-five general wards at Siriraj Hospital, Bangkok, Thailand, from July 2020 through December 2024.
Patients: Hospitalized adult patients receiving intravenous fluoroquinolones who met predefined IV-to-PO conversion criteria.
Methods: Wards were randomized 1:1 to either a sticker reminder intervention or standard care. In the intervention group, a reminder sticker was placed on the vital signs sheet of eligible patients. The primary outcome was the proportion of IV-to-PO conversion in the intention-to-treat (ITT) and modified intention-to-treat (mITT) populations.
Results: A total of 168 patients were enrolled (85 intervention, 83 control). In the ITT population, the IV-to-PO conversion rate was 58.8% in the intervention group versus 42.2% in the control group (p-value = 0.03). In the mITT population (patients meeting all conversion criteria), the intervention group had a significantly higher conversion rate (69.0% vs. 48.5%; p-value = 0.01). No significant differences were observed in clinical cure rates, in-hospital mortality, length of stay, duration of either IV FQ or PO FQ therapy.
Conclusion: A sticker reminder intervention effectively increases IV-to-PO FQ conversion among eligible patients without compromising clinical safety. Future large-scale…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 168 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.